

 $R_{esponse} E_{valuation} I_n N_{eurofibromatosis} S_{chwannomatosis} \\ INTERNATIONAL COLLABORATION$

- If sharing any data or information from these slides generated by the REiNS International Collaboration, please acknowledge the authors, group chairs, and specific working group.
- If using any information presented with a citation, please reference the primary source.

Assessing cutaneous neurofibromas in decentralized trials

Kavita Sarin, MD PhD, on behalf of the CNF Working Group

Stanford University

December 3, 2023



Unique characteristics of cNFs for decentralized trials

- Three dimensional objects •
- Different subtypes with variation in shape, compressibility and depth May have ill-defined borders •
- •
- Large range in numbers, color, and distribution •
- Skin is very personal ٠
- Location matters: cNFs can be in visible and • sensitive areas
- Pain/sensitivity is variable ٠
- Not static/ appearance and size can evolve • change with time
- No validated measurement tools for cNFs in • clinical trials
- Decentralized clinical trials in skin have not been used in pivotal trials for FDA approval





Core Domain Outcomes

Clinical assessment Anatomic location, change over time, cosmesis, number, pain, recurrence, visibility

Daily life impact Health-related quality of life, psychological functioning, stigma

Patient satisfaction Satisfaction with treatment^{†‡}, tolerability and adverse effects of treatments^{†‡}, treatment burden^{†‡}

> Perception of health Self-esteem, self-image

> > A

Clinical assessment Size and volume^{†‡}

Daily life impact Physical functioning impact*+, social functioning+‡

> Perception of health Perceived severity *‡

> > В

Body surface area covered Economic burden Growth rate over time Intimacy Irritation Pruritus Wound healing

С

Results of the REiNS e-Delphi process 2022-3 Fertitta L, et a;. Br J Dermatol. 2023 Oct 25 Epub



Clinical Assessment

- Individual features of cNFS: volume height, area, diameter, subtype change over time
- Global features of cNFS: number, distribution, change over time, global assessment of severity
- Cutaneous adverse effect of treatment (i.e. rash, erythema, ulceration, dermatitis)



Methods of remote evaluation of cNFs

- Patient self measurements (sending calipers/rulers)
- Photographs based measurements
- Televisit measurements
- Visiting a local care provider for measurements / visibility scale
- Imaging based methods: ultrasound/ MRI



Measurement tradeoffs *examples


Method	Pro	Con	
Self-measurement	Can be conducted at home Can measure all 3 dimensions	Participants may measure differently Requires training and may be more difficult to standardize	
Photographs	Can be conducted at home Measurements can be done centrally Allows confirmation	Variable quality Some may feel uncomfortable Height measurement is difficult	
Televisit	May help guide either self- measurement or self-photography	Time consuming	
Local care provider	Can help with areas hard to measure. May be more appealing to participants	Feasibility: unclear if each site would need an IRB, Interrater and intersite variability	
Imaging	Measures depth below skin	Costly, time consuming, unclear if accuracy is better than other measures Models may very across sites	



Which method of CNF measurement do you think will be most accurate?



Which method of deco	centralized CNF measurement do you prefer?	
Participant measures t	s their own CNFs using a standardized ruler or caliper	0%
Participant submits m	nobile photographs including a sticker for standardization	0%
Participant joins a tele	levisit (zoom) and measures CNFS under guidance of an investigator	0%
Participant visits a loca	cal care provider for CNF measurement	0%
Participannt visit an in	imaging facility (MRI/US) for CNF imaging	0%





Adverse Effects Assessments:


Common Terminology Criteria for Adverse Events (CTCAE)



CTCAE Term	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5
Rash acneiform	Papules and/or pustules	Papules and/or pustules	Papules and/or pustules	Life-threatening	Death
	covering <10% BSA, which	covering 10 - 30% BSA, which	covering >30% BSA with	consequences; papules	
	may or may not be associated	may or may not be associated	moderate or severe	and/or pustules covering any	
	with symptoms of pruritus or	with symptoms of pruritus or	symptoms; limiting self-care	% BSA, which may or may not	
	tenderness	tenderness; associated with	ADL; associated with local	be associated with symptoms	
		psychosocial impact; limiting	superinfection with oral	of pruritus or tenderness and	
		instrumental ADL; papules	antibiotics indicated	are associated with extensive	
		and/or pustules covering >		superinfection with IV	
		30% BSA with or without mild		antibiotics indicated	
		symptoms			


Definition: A disorder characterized by an eruption of papules and pustules, typically appearing in face, scalp, upper chest and back.







Can measurements of tumor height, area or volume be reliably obtained through photographs ?



mobile



3D Full body

3D regional



Current studies with remote photographic evaluation of cNFs

- NF1 Genetic Study Cohort 5000 self-obtained photographs from 675 participants
 50 participants submitted both mobile photos (7 body sites) and also had in
 - clinic full body photography
 - Drs. Sarin and Romo rated # of cNFS 1-10, 11-100, 101-500, > 500.
 - Number of cNFs had high agreement between mobile and clinic photos:
 Kappa = 0.74 for, 1 within 1 level
- CNF Consortium Australian PI International recruitment: Patient photography and GWAS from saliva. 470 recruited but aiming for 2000. Working on AI to analyze photography from 3 body areas to determine cNF severity.
- French & Australian CNF outcome measure study: exploring 2D and 3D photographs for assessment of cNF response after procedures. 55 patients across 3 timepoints. Photography pre and post treatment. Challenges inherent in photographic series comparing appearance requires consistent photography.



Please do not put content in this area to save space for captioning. Delete this text before final presentation

GAPS in implementing decentralized trials for cNFs

- No validated measurements for CNFS in clinical trials
- Lack of studies comparing accuracy of remote measurement methods

Variability in Mobile photographs



•

Next Steps

Evaluating measurements for cNF in clinical trials (leads: Drs. Fertitta and Berman) 2024 subgroup initiatives Recommendations for Machine learning for decentralized trials in cNF assessment cNF (leads: Drs. Berman (leads: Drs. Petersen and Fertitta) and Sarin)



Acknowledgements

- Drea Petersen
- Ashley Cannon
- Andrés Lessing
- Scott Plotkin
- Laura Fertitta
- Yemima Berman
- Chris Moertel

- Khaled Ezzedine
- Deeann Wallis
- Dominique Pichard
- Claas Roehl
- Anat stemmer-Rachamimov
- Pierre Wolkenstein
- Carlos Romo
- Dianna Xinghu

And the rest of the REiNS CNF Working group